These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32618490)

  • 1. An overview of nanomedicines for neuron targeting.
    Garcia-Chica J; D Paraiso WK; Tanabe S; Serra D; Herrero L; Casals N; Garcia J; Ariza X; Quader S; Rodriguez-Rodriguez R
    Nanomedicine (Lond); 2020 Jul; 15(16):1617-1636. PubMed ID: 32618490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual and multi-targeted nanoparticles for site-specific brain drug delivery.
    Luo Y; Yang H; Zhou YF; Hu B
    J Control Release; 2020 Jan; 317():195-215. PubMed ID: 31794799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
    van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting specific cells in the brain with nanomedicines for CNS therapies.
    Zhang F; Lin YA; Kannan S; Kannan RM
    J Control Release; 2016 Oct; 240():212-226. PubMed ID: 26686078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.
    Furtado D; Björnmalm M; Ayton S; Bush AI; Kempe K; Caruso F
    Adv Mater; 2018 Nov; 30(46):e1801362. PubMed ID: 30066406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
    Tam VH; Sosa C; Liu R; Yao N; Priestley RD
    Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comprehensive Review on Nanomedicine: Promising Approach for Treatment of Brain Tumor through Intranasal Administration.
    Bahadur S; Prakash A
    Curr Drug Targets; 2023; 24(1):71-88. PubMed ID: 36278468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
    Zhao X; Ye Y; Ge S; Sun P; Yu P
    Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
    Bhattacharjee S; Brayden DJ
    Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevant Physicochemical Descriptors of "Soft Nanomedicines" to Bypass Biological Barriers.
    Nino-Pariente A; Nebot VJ; Vicent MJ
    Curr Pharm Des; 2016; 22(9):1274-91. PubMed ID: 26675217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in drug delivery and targeting to the brain.
    Sethi B; Kumar V; Mahato K; Coulter DW; Mahato RI
    J Control Release; 2022 Oct; 350():668-687. PubMed ID: 36057395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in nanomaterials for neural applications: opportunities and challenges.
    Sisubalan N; Shalini R; Ramya S; Sivamaruthi BS; Chaiyasut C
    Nanomedicine (Lond); 2023 Nov; 18(26):1979-1994. PubMed ID: 38078433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in nanomedicines for diagnosis of central nervous system disorders.
    Zhang X; Zhou J; Gu Z; Zhang H; Gong Q; Luo K
    Biomaterials; 2021 Feb; 269():120492. PubMed ID: 33153757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
    Muthu MS; Singh S
    Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
    Gu W; Meng F; Haag R; Zhong Z
    J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
    Pearce AK; O'Reilly RK
    Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.